Navigation Links
Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for Suprax(R) 400 mg Tablets in the U.S.
Date:6/23/2008

BALTIMORE, June 23 /PRNewswire/ -- Lupin Pharmaceuticals, a subsidiary of Lupin Ltd., announced today that the Company has entered into a promotion agreement for Suprax(R) 400 mg Tablets with ASCEND Therapeutics, Inc.

Under the terms of the alliance, ASCEND Therapeutics will initiate promotion of the product in the U.S. in the month of June 2008. ASCEND has a 50-person Women's Health sales force which will detail the product primarily to Obstetricians and Gynecologists (OB/GYNs). Lupin will continue to promote the product to Pediatricians and Family Practitioners.

The antibiotic market for treatment of Urinary Tract Infections (UTIs) is USD 450 million, and the OB/GYN area is among the top three physician specialties prescribing antibiotics for treatment of UTIs.

"We are pleased to enter into this strategic alliance with ASCEND. We believe ASCEND's existing equity with the OB/GYN specialty will help Lupin to fully explore and leverage an additional opportunity for promoting Suprax(R) 400 mg Tablets. This alliance reflects Lupin's commitment to building the Suprax(R) franchise and enhancing the value of brand business in the U.S.," said Vinita Gupta, President, Lupin Pharmaceuticals, Inc.

"We are very excited about adding Suprax(R) 400 mg Tablets to our portfolio of products which we market to Women's Health professionals," said Jay Bua, President, ASCEND Therapeutics. "There are over 8 million patient visits for UTIs each year, with the vast majority of these experienced by women. Suprax(R) 400 mg Tablets is an established antibiotic with a favorable safety profile and proven track record in effectively treating UTIs and other bacterial infections. We very much look forward to a long and productive collaboration with Lupin."

About Lupin

Lupin Pharmaceuticals, Inc., headquartered in Baltimore, Maryland, is the wholly owned U.S. subsidiary of Mumbai-based Lupin Limited, a leading Indian pharmaceutical company. Lupin Limited develops, manufactures and markets a wide range of quality, affordable generic and branded generic formulations and APIs for both the developed and the developing markets of the world. Twelve of Lupin's facilities have been inspected and approved by the U.S. Food & Drug Administration.

For the year ended March 2008, Lupin's consolidated revenues and profit after tax were USD 660.23 million and USD 97.21 million, respectively.

The Company has secured a global leadership position in anti-TB products and cephalosporins and has a significant presence in the areas of cardiovasculars (prils and statins), diabetology, asthma and NSAIDs. Currently positioned among the top five pharmaceutical companies in India, the Company is committed to achieving sustainable earnings and growth for all its stakeholders. For more information, visit http://www.lupinpharmaceuticals.com.

About ASCEND Therapeutics

ASCEND Therapeutics is a biopharmaceutical company focused on the use of transdermal drug delivery technology to overcome therapeutic barriers and raise the standard of care for certain chronic conditions. For more information about ASCEND, you may visit the company's web site at http://www.ascendtherapeutics.com.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.

Suprax(R) is a registered trademark of Lupin Pharmaceuticals, Inc.

For More Information:

Contact: Atul Gokhale

General Manager -- Marketing

1-410-576-2000


'/>"/>
SOURCE Lupin Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lupin Receives USFDA Approval for Topiramate Tablets
2. Lupin Launches Ramipril Capsules
3. Lupin Receives USFDA Approval for Escitalopram Oxalate Tablets
4. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
5. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
6. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
7. Navitas Opens New Cancer Rehabilitation Center in Albuquerque in Conjunction With New Mexico Cancer Centers
8. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
9. Service-to-Sales Transformation at Contact Centers Hinges on Soft Skills
10. The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers
11. Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 26, 2016 Story ... operating models within the health care industry is causing ... efficiency , Deloitte offers a suite of solutions ... issues impacting efficient cost optimization: labor resource analysis, revenue ... services facilitate better outcomes and better economics ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology: